Management of Self-injurious Behaviors in Children with Neurodevelopmental Disorders: A Pharmacotherapy Overview

Pharmacotherapy
Ashley SabusAllison Beck Blackmer

Abstract

Neurodevelopmental disorders (NDDs), a group of disorders affecting ~1-2% of the general population, are caused by changes in brain development that result in behavioral and cognitive alterations, sensory and motor changes, and speech and language deficits. Neurodevelopmental disorders encompass a heterogeneous group of disorders including, but not limited to, Smith-Magenis syndrome, Lesch-Nyhan disease, cri du chat syndrome, Prader-Willi syndrome, pervasive developmental disorders, fragile X syndrome, Rett syndrome, Cornelia de Lange syndrome, and Down syndrome. Self-injurious behaviors (SIBs) are common in children with NDDs; depending on the specific NDD, the incidence of SIBs is nearly 100%. The management of SIBs in this population is complex, and little high-quality data exist to guide a consistent approach to therapy. However, managing SIBs is of the utmost importance for the child as well as the family and caregivers. Behavior therapies must be implemented as first-line therapy. If behavioral interventions alone fail, pharmacotherapy becomes an essential part of management plans. The limited available evidence for the use of common pharmacologic agents, such as second-generation antipsychotics, and less common agents, s...Continue Reading

References

Jul 1, 1976·Journal of Neurology, Neurosurgery, and Psychiatry·C D FrithR W Watts
Apr 1, 1990·Biological Psychiatry·H KarsJ M van Ree
Apr 20, 1974·Lancet·T I Mizuno, Y Yugari
Dec 1, 1994·International Journal of Cardiology·A M Amanullah
Jan 1, 1994·Journal of Applied Behavior Analysis·B A IwataG S Richman
Nov 1, 1993·Journal of the American Academy of Child and Adolescent Psychiatry·M CampbellM Ernst
Mar 1, 1993·Journal of Autism and Developmental Disorders·C OliverJ Corbett
May 1, 1993·Journal of the American Academy of Child and Adolescent Psychiatry·J P KemphR L Miller
Jan 12, 2000·Journal of Child and Adolescent Psychopharmacology·P BlewS Thibadeau
Jun 8, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·B H KingE H Cook
Oct 20, 2001·Journal of Child and Adolescent Psychopharmacology·D J PoseyC J McDougle
Jan 5, 2002·Seminars in Pediatric Neurology·G Stores
Jul 24, 2002·The International Journal of Neuropsychopharmacology·Nathan A ShapiraWayne K Goodman
Aug 2, 2002·The New England Journal of Medicine·James T McCrackenUNKNOWN Research Units on Pediatric Psychopharmacology Autism Network
Aug 8, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Christopher J McDougleDavid J Posey
Aug 15, 2002·Journal of Developmental and Behavioral Pediatrics : JDBP·Thomas A Rugino, Teresa C Samsock
Jul 16, 2003·Journal of Applied Behavior Analysis·Gregory P HanleyBrandon E McCord
Jun 5, 2004·American Journal of Mental Retardation : AJMR·Nathan A ShapiraDaniel J Driscoll
Oct 27, 2004·Journal of the American Academy of Child and Adolescent Psychiatry·Frank J SymonsGeorge Realmuto
Jul 5, 2005·The American Journal of Psychiatry·UNKNOWN Research Units on Pediatric Psychopharmacology Autism Network
Jan 25, 2006·Journal of Intellectual Disability Research : JIDR·L LecavalierJ Wiltz
Oct 3, 2006·International Clinical Psychopharmacology·Stacey WassermanEric Hollander
Oct 5, 2006·Journal of Autism and Developmental Disorders·Gahan J PandinaFiona Dunbar
Oct 31, 2006·Journal of Child and Adolescent Psychopharmacology·Eric HollanderSherie Novotny
Oct 31, 2007·Pediatrics·Scott M MyersUNKNOWN American Academy of Pediatrics Council on Children With Disabilities
Jan 5, 2008·American Journal of Mental Retardation : AJMR·Scott S HallAllan L Reiss
Mar 5, 2008·Journal of Child and Adolescent Psychopharmacology·Richard P MaloneJacqueline R Cater
Nov 1, 2007·Current Genomics·K M J van Loo, G J M Martens
Oct 3, 2009·Journal of the American Academy of Child and Adolescent Psychiatry·Ronald N MarcusMichael G Aman
Dec 17, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eric HollanderEvdokia Anagnostou
Jul 20, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Vala RezaeiShahin Akhondzadeh
Sep 2, 2010·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Kiah BertoglioRobert L Hendren
Nov 10, 2010·Brain Research·Craig A EricksonChristopher J McDougle
Jul 9, 2011·Pharmacopsychiatry·R ZhangK Ying
Aug 10, 2011·Journal of Child and Adolescent Psychopharmacology·Logan K WinkChristopher J McDougle
Feb 22, 2012·Biological Psychiatry·Antonio Y HardanRabindra Tirouvanziam
Mar 13, 2012·Journal of Intellectual Disability Research : JIDR·C RichardsJ Moss
Apr 1, 2008·Behavior Analysis in Practice·Jeffrey H TigerJennifer Bruzek
Apr 17, 2012·Research in Developmental Disabilities·Johnny L Matson, Nicole C Turygin
May 3, 2012·Psychopharmacology·Kimberly A StiglerChristopher J McDougle

❮ Previous
Next ❯

Citations

May 23, 2019·Pharmacotherapy·C Lindsay DeVane
May 1, 2021·Postgraduate Medical Journal·Lamiaa HamieMazen Kurban
Jun 2, 2021·Pediatric Dermatology·Larissa HinesJennifer L Hand

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here